Canada First to Receive New Treatment Option for Liver Cancer Patients

DC Bead LUMI™ Radiopaque Drug-Eluting Bead Offers Interventional Radiologists in Canada a Next Generation Treatment Option for Liver Cancer Patients

OTTAWA, Dec. 5, 2016 /CNW/ - BTG International Canada Inc., a part of global specialist healthcare company BTG (LSE: BTG), today announced the commercial launch of DC Bead LUMI™ in Canada. Today's launch represents the first market commercialization of DC Bead LUMI™ in the world, with regulatory clearances and launches planned for additional markets worldwide.

BTG International Canada Inc. received Health Canada approval for DC Bead LUMITM in August, 2016.

DC Bead LUMI™ is the first available radiopaque embolic drug-eluting bead that can be loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer1 or with irinotecan for the treatment of malignant colorectal cancer metastasized to the liver (mCRC ).2

Drug-eluting beads are used in trans-arterial chemoembolization (TACE), which is a minimally invasive liver cancer treatment.  Drug-eluting bead TACE combines the deliberate blocking of the blood supply to the tumour and delivery of a local, controlled, sustained dose of chemotherapy directly to the tumour.3

DC Bead LUMI™ is a next generation development of DC Bead®, the market leading drug-eluting embolic bead that has the potential to revolutionize the treatment of liver tumours.2

The unique visibility of DC Bead LUMI™ helps optimize patient treatment by enabling real-time visible confirmation of bead location during and after the embolization procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.4

Canadian Hospital First to Offer Treatment Option

Sunnybrook Health Sciences Centre in Toronto, Canada was the first institution to perform the procedure.

"The LUMI TACE beads really delivered. They were what one hoped for; it was easy to see under fluoroscopy, single shot and cone beam CT," said Dr. Chris Dey, Staff Vascular/Interventional Radiologist, Sunnybrook Health Sciences Centre and Assistant Professor, Faculty of Medicine, University of Toronto. "You can appreciate actual bead deposition in the liver for the first time, flow patterns much more reliably and make intra-procedural adjustments or determine end points more precisely."

DC Bead LUMI™ is developed on the same technology platform and to the same high standard as DC Bead®, building upon its market leading clinical performance.

"DC Bead LUMI™ allows for the personalization of liver cancer treatment like never before, providing the vision, precision and assurance that the treatment is getting where it needs to be," added Frank Maiorino, Director, Marketing at BTG International Canada Inc.

"Being the first country to launch this revolutionary product demonstrates the importance of the Canadian market to BTG worldwide," concludes Brad Pearson, Director, Commercial Operations at BTG International Canada Inc.

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.

About BTG Interventional Medicine

BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavours to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com

References:
1.      http://www.liver.ca/liver-disease/types/liver-cancer.aspx 
2.      DC Bead LUMI™ Radiopaque Embolic Drug-Eluting Bead Canadian Instructions for Use V.1
3.      http://bead.btg-im.com/products/canada-132/dcbead-3/chemoembolisation
4.      Duran et al. Theranostics 6(1) 2016:28-39

SOURCE BTG International Canada Inc.

Image with caption: "DC Bead LUMI™ Radiopaque Drug-Eluting Bead Offers Interventional Radiologists in Canada a Next Generation Treatment Option for Liver Cancer Patients (CNW Group/BTG International Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20161205_C4899_PHOTO_EN_830883.jpg

For further information: Canadian Media Inquiries: Eileen Tobey, beSPEAK Communications Inc., Eileen@bespeakcommunications.com, +1 416 540 4047; International Media Inquiries: Chris Sampson, Director of Corporate Communications, +44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178; Investor Relations Inquiries: Andy Burrows, VP Corporate & Investor Relations, +44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890